[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Ascendis Pharma Endocrinology Division A\u002FS\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":72},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,41],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":20,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":25,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100502316",false,"NCT05820672","A US Non-interventional, Effectiveness and Safety Study of Patients Treated With SKYTROFA","A US Multi-center, Prospective, Non-interventional, Long Term, Effectiveness and Safety Study of Patients Treated With SKYTROFA (Lonapegsomatropin)","SkybriGHt","Inclusion Criteria:\n\n* Patients who are on treatment with SKYTROFA (lonapegsomatropin)\n* Patients being clinically managed in USA\n* Patients with an appropriate written informed consent\u002Fassent as applicable for the age of the patient\n\nExclusion Criteria:\n\n* Patients participating in any interventional clinical study","ALL",{"count":18,"type":19},900,"ESTIMATED","5 Years","OBSERVATIONAL","The goal of this study is to genrate evidence on long-term effectiveness and safety of SKYTROFA (lonapegsomatropin) in patients with growth hormone deficiency under routine clinical care",[24],"Growth Hormone Deficiency",[26,27],"Human Growth Hormone","SKYTROFA","RECRUITING","2026-04-20",{"date":31,"type":32},"2026-04-21","ACTUAL",{"date":34,"type":32},"2023-03-20",{"date":36,"type":19},"2033-03",{"name":38,"class":39},"Ascendis Pharma Endocrinology Division A\u002FS","INDUSTRY",27,{"id":42,"slug":4,"hasResults":10,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":10,"sex":16,"minAge":48,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":52,"conditions":53,"keywords":54,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":70,"leadSponsor":71,"locationsCount":40},"100498843","NCT05775523","A Post-Authorisation Safety Study (PASS) of Patients Treated With Lonapegsomatropin","A Prospective, Non-interventional (NIS), Long-term, Post-Authorisation Safety Study (PASS) of Patients Treated With Lonapegsomatropin","SkyPASS","Inclusion Criteria:\n\n* Paediatric patients with GHD who are on treatment with lonapegsomatropin\n* Patients being clinically managed in Europe or the USA\n* Appropriate written informed consent\u002Fassent as applicable for the age of the patient\n* Patients willing to comply with follow-up requirements of the study\n\nExclusion Criteria:\n\n* Patients participating in any interventional clinical trial for short stature\n* Patients being treated with a GH or IGF-1 therapy, other than lonapegsomatropin, at enrollment\n* Patients for whom treatment with lonapegsomatropin is contraindicated\n* Patients with closed epiphyses\n* Patients with active malignant tumours\n* Patients under antitumour therapy within the past 12 months prior to instituting GH therapy\n* Hypersensitivity to somatropin or any of the excipients in lonapegsomatropin","1 Year","18 Years",{"count":51,"type":19},500,"The goal of this study is to further characterise the potential long-term safety risks of lonapegsomatropin in patients treated with lonapegsomatropin under real-world conditions in the post-marketing setting.",[24],[26,55,56,57,58,59,60,61,62,63,24,64,65,46],"hGH","rhGH","GHD","Long Acting Growth Hormone","Lonapegsomatropin","Prodrug","Growth Failure","Growth Hormone Replacement Therapy","Sustained Release Growth Hormone","TransCon hGH","Skytrofa","2026-02-02",{"date":68,"type":32},"2026-02-04",{"date":34,"type":32},{"date":36,"type":19},{"name":38,"class":39},""]